Amgen

This sponsor has funded 143 studies across 51 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
2353 Finalised Yes No
2356 Finalised Yes Yes
2382 Finalised Yes No
2385 Ongoing Yes No
2388 Ongoing Yes No
2561 Ongoing Yes No
3180 Finalised Yes Yes
5345 Finalised Yes Yes
5605 Finalised Yes Yes
5641 Finalised Yes Yes
5644 Finalised Yes Yes
5647 Finalised Yes Yes
5681 Finalised Yes Yes
5687 Finalised Yes Yes
6210 Finalised Yes Yes
6658 Finalised No Yes
8054 Finalised Yes Yes
11186 Finalised No Yes
11662 Finalised Yes Yes
11891 Finalised No Yes
13328 Finalised Yes Yes
13518 Finalised Yes Yes
13676 Ongoing Yes No
13794 Finalised Yes Yes
15128 Ongoing No No
15153 Finalised Yes Yes
16291 Finalised Yes Yes
16302 Finalised Yes Yes
16626 Finalised Yes Yes
17198 Finalised Yes Yes
17390 Finalised Yes Yes
17410 Finalised Yes Yes
17829 Finalised Yes Yes
17848 Ongoing No No
17915 Finalised Yes Yes
18060 Finalised No Yes
18108 Ongoing Yes Yes
18114 Finalised Yes Yes
18402 Finalised Yes Yes
18916 Finalised Yes Yes
18923 Finalised Yes Yes
19053 Ongoing Yes No
19116 Finalised Yes Yes
19126 Finalised Yes Yes
19156 Finalised Yes Yes
19680 Finalised Yes Yes
19718 Finalised Yes Yes
19961 Finalised Yes Yes
20043 Finalised Yes Yes
20687 Finalised Yes Yes
21542 Ongoing Yes No
21914 Finalised Yes Yes
22075 Finalised Yes Yes
23186 Finalised No Yes
23268 Finalised Yes Yes
24079 Ongoing No No
24541 Finalised Yes Yes
24626 Finalised Yes Yes
24775 Finalised Yes Yes
24954 Ongoing No No
25381 Finalised Yes Yes
25858 Finalised Yes Yes
26165 Ongoing No No
26372 Finalised Yes Yes
26499 Finalised Yes Yes
26530 Finalised Yes Yes
26983 Finalised Yes Yes
27121 Ongoing No No
27161 Finalised Yes Yes
27382 Finalised Yes Yes
27559 Ongoing No No
27845 Finalised Yes Yes
28762 Finalised Yes Yes
29415 Ongoing No No
29685 Ongoing No No
30072 Finalised Yes Yes
30108 Finalised Yes Yes
30334 Finalised Yes Yes
30346 Ongoing No No
30491 Planned No No
30506 Finalised No No
30534 Finalised Yes Yes
30748 Finalised Yes Yes
31161 Finalised No Yes
31188 Finalised Yes Yes
31213 Finalised Yes Yes
31796 Ongoing Yes No
31967 Finalised Yes Yes
32133 Finalised Yes Yes
32139 Finalised Yes Yes
32183 Finalised Yes Yes
32437 Finalised Yes Yes
32995 Ongoing Yes No
33657 Finalised Yes Yes
33745 Ongoing Yes No
33862 Ongoing No No
34153 Finalised Yes Yes
34220 Finalised Yes Yes
34590 Finalised Yes Yes
34701 Finalised Yes Yes
34832 Finalised Yes Yes
35042 Finalised Yes No
36072 Ongoing No No
36417 Ongoing Yes No
36684 Finalised No Yes
37160 Ongoing No No
37499 Ongoing No No
37529 Finalised Yes Yes
37579 Ongoing No No
37799 Ongoing No No
37838 Finalised Yes Yes
37877 Finalised Yes Yes
38357 Finalised Yes Yes
38906 Finalised No Yes
39611 Finalised Yes Yes
40607 Finalised Yes Yes
40706 Ongoing No No
41626 Finalised Yes Yes
41675 Finalised Yes Yes
42393 Ongoing No No
43115 Finalised No Yes
44300 Finalised Yes Yes
44961 Finalised No Yes
45083 Finalised Yes Yes
45236 Planned No No
45799 Finalised Yes Yes
46267 Finalised Yes No
46292 Finalised Yes Yes
46337 Finalised No Yes
46340 Finalised Yes Yes
46655 Ongoing No No
46882 Finalised No Yes
49061 Finalised Yes Yes
49101 Ongoing No No
49104 Finalised No Yes
49271 Planned No No
49757 Ongoing Yes No
103648 Ongoing Yes No
104114 Planned No No
104308 Ongoing No No
104428 Planned No No
107685 Ongoing No No
107858 Planned No No

PAS by Risk Management Plan (RMP) requirement

Amgen

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.